Paper35967142
The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression.
Pantarotto M and 8 others. Cureus, 2022. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression. Papers, record 35967142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35967142
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 36819952 | Correction: The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression. | https://conductscience.org/library/papers/36819952 |
Source PubMed
References24
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33598792 | Sarcoid-like reaction in cases treated by checkpoint inhibitors. | Med Oncol | 2021 | https://conductscience.org/library/papers/33598792 | PubMed |
| 2 | 30853796 | Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. | Curr Oncol | 2019 | https://conductscience.org/library/papers/30853796 | PubMed |
| 3 | 29763666 | Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. | J Thorac Oncol | 2018 | https://conductscience.org/library/papers/29763666 | PubMed |
| 4 | 29433571 | Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. | J Immunother Cancer | 2018 | https://conductscience.org/library/papers/29433571 | PubMed |
| 5 | 29162153 | Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. | J Immunother Cancer | 2017 | https://conductscience.org/library/papers/29162153 | PubMed |
| 6 | 32402357 | Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. | Clin Chest Med | 2020 | https://conductscience.org/library/papers/32402357 | PubMed |
| 7 | 33330555 | Sarcoidosis and Cancer: A Complex Relationship. | Front Med (Lausanne) | 2020 | https://conductscience.org/library/papers/33330555 | PubMed |
| 8 | 29698718 | Drug-Induced Sarcoidosis-Like Reactions. | Chest | 2018 | https://conductscience.org/library/papers/29698718 | PubMed |
| 9 | 34761878 | Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response. | Thorac Cancer | 2021 | https://conductscience.org/library/papers/34761878 | PubMed |
| 10 | 29898781 | Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment. | J Immunother Cancer | 2018 | https://conductscience.org/library/papers/29898781 | PubMed |
| 11 | 34855255 | Development of thoracic sarcoid reactions associated with complete response to anti-PD-1 therapy in a patient with advanced cutaneous squamous cell carcinoma. | J Eur Acad Dermatol Venereol | 2022 | https://conductscience.org/library/papers/34855255 | PubMed |
| 12 | 33263945 | Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case. | Dermatol Ther | 2021 | https://conductscience.org/library/papers/33263945 | PubMed |
| 13 | 34724392 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34724392 | PubMed |
| 14 | 28231584 | Characteristics of Sarcoidosis in Patients with Previous Malignancy: Causality or Coincidence? | Respiration | 2017 | https://conductscience.org/library/papers/28231584 | PubMed |
| 15 | 32099495 | Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives. | Lung Cancer (Auckl) | 2019 | https://conductscience.org/library/papers/32099495 | PubMed |
| 16 | 34452793 | Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. | Eur J Cancer | 2021 | https://conductscience.org/library/papers/34452793 | PubMed |
| 17 | 34425404 | Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. | Eur J Cancer | 2021 | https://conductscience.org/library/papers/34425404 | PubMed |
| 18 | 30030656 | The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring. | Curr Oncol Rep | 2018 | https://conductscience.org/library/papers/30030656 | PubMed |
| 19 | 32248071 | Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. | Eur J Cancer | 2020 | https://conductscience.org/library/papers/32248071 | PubMed |
| 20 | 33433837 | Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital. | Clin Transl Oncol | 2021 | https://conductscience.org/library/papers/33433837 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40647656 | Drug-Induced Sarcoid-like Reactions Associated to Targeted Therapies and Biologic Agents. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/40647656 | PubMed |
| 39894895 | A Unique Case of Poorly Differentiated Neuroendocrine Carcinoma With Brain and Bilateral Adrenal Metastases. | Cancer Rep (Hoboken) | 2025 | https://conductscience.org/library/papers/39894895 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD68 | 968 | PubTator's text mining | https://conductscience.org/library/genes/968 | NCBI Gene |
| CD80 | 941 | PubTator's text mining | https://conductscience.org/library/genes/941 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| MAP2K7 | 5609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35967142
GET https://conductscience.org/api/papers/v1/35967142/references?page=2